Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction

Circulation

Volumn 96, Issue 2, 1997, Pages 442-447

  Vaughan, Douglas E ^a   Rouleau, Jean Lucien ^b   Ridker, Paul M ^c,d   Arnold, J Malcolm O ^e   Menapace, Francis J ^f   Pfeffer, Marc A ^c,d  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MONTREAL HEART INSTITUTE   (Canada)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e LONDON HEALTH SCIENCES CENTRE   (Canada)

^f GEISINGER MEDICAL CENTER   (United States)

Author keywords

Angiotensin; Bradykinin; Fibrinolysis; Myocardial infarction; Plasminogen activators; Renin; Thrombolysis

Indexed keywords

ANGIOTENSIN; ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAMIPRIL; RENIN; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BLOOD CLOT LYSIS; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FIBRINOLYSIS; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0030811106     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.2.442     Document Type: Article

References (41)

1. Saksela O, Rifkin DB. Cell-associated plasminogcn activation: regulation and physiologic functions. Am Rev Cell Biol. 1988;4:93-126.
2. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischemic heart disease in the Northwick Park Heart study. Lancet. 1993;342:1076-1079.
3. Hamsten A, Wiman B, deFaire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313: 1557-1563.
4. Hamsten A, Walldius G, Szamosi A, Blombäck M. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
5. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney A. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem. 1993;268:10739-10745.
6. Eriksson P, Kallin B, Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen activator inhibitor-1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA. 1995;92:1851-1855.
7. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest. 1995;95:995-1001.
8. Feener EP, Northrup JM, Aiello LP, King GL. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest. 1995; 95:1353-1362.
9. Ridker PM, Gaboury CL, Conlin PR, Scely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Circulation. 1993;87:1969-1973.
10. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest. 1995;96:2515-2520.
11. Erdos E, Skidgel RA. The angiotensin I converting enzyme. Lab Invest. 1987;56:345-348.
12. Brown NJ, Nadeau J, Vaughan DE. Stimulation of tissue-type plasminogcn activator in vivo by infusion of bradykinin. Thromb Haemost. 1997;77:522-525.
13. Smith D, Gilbert M, Owen WG. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood. 1985;66: 835-839.
14. Emeis JJ, Tranquille N. On the role of bradykinin in secretion from vascular endothelial cells. Agents Actions. 1992;38:285-291.
15. Pfeffer MA, Braunwald LA, Moye L, Basta EJ, Drown EJ, Cuddy TE, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327:669-677.
16. Yusuf S, Pepine CJ, Garces C, Pouleur H. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992;340:1173-1178.
17. Lonn EM, Yusuf S, Jha P, Montague TJ. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 1994;90:2056-2069.
18. Pfeffer MA, LaMotte FS, Arnold JM. Rouleau JL. Titration of angiotensin converting enzyme inhibition in acute anterior infarction: the Healing and Early Afterload Reducing Therapy (HEART) study. Circulation. 1995:92(suppl I):I-19. Abstract.
19. Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor. Circulation. 1989;79:101-106.
20. Grimaudo V, Hauert J, Backmann F, Kruithof EKO. Diurnal variation of the fibrinolytic system. Thromb Haemost. 1988;59: 495-499.
21. Verheijen JH, Chang GTG, Kluff C. Evidence for the occurrence of a fast acting inhibitor of tissue-type plasminogen activator in plasma. Thromb Haemost. 1984;51:392-395.
22. Ridker PM, Vaughan DE, Stampfer MJ. Manson JE, Shen C, Newcomer L, Goldhaber SZ, Hennekens CH. Baseline fibrinolytic state and the risk of future venous thrombosis: a prospective study of endogenous tissue plasminogen activator and plasminogen activator inhibitor. Circulation. 1992;85:1822-1827.
23. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and the risk of future myocardial infarction. Lancet. 1993;341:1165-1168.
24. Aimer LO, Ohlin H. Elevated levels of the rapid inhibitor of plasminogen activator (t-PA) in acute myocardial infarction. Thromb Res. 1987;47:335-339.
25. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. A prospective study of tissue-type plasminogen activator and the risk of stroke. Lancet. 1994;343:940-943.
26. Chandler WL, Veita RC, Fellingham GW, Levy WC. Fibrinolytic response during exercise and epinephrine infusion in the same subjects. J Am Coll Cardiol. 1992;92:1412-1420.
27. Garahedian HD, Gold HK, Leinbach RC. Comparative properties of two clinical preparations of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. J Am Coll Cardiol. 1987;9:599-607.
28. Wiman B. Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease. Thromb Haemost. 1995;74:71-76.
29. Fujii S, Abendschein DR, Sobel BE. Augmentation of plasminogen activator inhibitor type I activity by thrombosis and by thrombolysis. J Am Coll Cardiol. 1991;18:1547-1554.
30. Wright RA, Flapan AD, Alberti KGMM, Ludlam CA, Fox KAA. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol. 1994;24:67-73.
31. Zuanetti G, Maggioni AP, Latini R, Franzosi MG. The early beneficial effect of treatment with oral ACE-inhibitors in patients with acute MI. Circulation. 1995;92(suppl I):I-24. Abstract.
32. Lucore CL, Sobel BE. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. Circulation. 1988;77:660-669.
33. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of renin-sodium profile with risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991;324: 1098-1104.
34. Cambien F, Poirer O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, Tiret L, Amouyel P, Alhenc-Gelas F, Soubrier F. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359:641-644.
35. Ludwig E, Corneli PS, Anderson JL, Marshall HW, Lalouel JM, Ward RH. Angiotensin-converting enzyme gene polymorphism is associated with myocardial infarction but not with development of coronary stenosis. Circulation. 1995;91:2120-2124.
36. Pedersen OD, Gram JJ, Baggar H, Keller N, Jespersen J. Regulation of tissue-type plasminogen activator-mediated fibrinolysis by plasminogen activator inhibitor-1 in patients with ischemic heart disease: possible unfavorable effects of diuretics. Coron Artery Dis. 1994;5:617-623.
37. Vaughan DE, Rouleau JL, Pfeffer MA. Role of fibrinolytic system in preventing myocardial infarction. Eur Heart J. 1995;16(K):31-36.
38. McGil JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes. 1994;43:104-109.
39. Oikawa T, Freeman M, Lo W, Vaughan DE, Fogo A. Modulation of plasminogen activator inhibitor-1 (PAI-1) in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int. 1997;51:164-172.
40. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med. 1993;329:1456-1462.
41. Hamdan AD, Quist WC, Gagne JB, Feener EP. Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta. Circulation. 1996;93:1073-1078.